{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:52:41Z","timestamp":1793141561830,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1097\/tp.0000000000000741","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T11:53:27Z","timestamp":1432814007000},"page":"2356-2363","source":"Crossref","is-referenced-by-count":197,"title":["A Phase I\/II Trial of the Interleukin-6 Receptor\u2013Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Ashley A.","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jua","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kahwaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shili","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechu","family":"Puliyanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reinsmoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Villicana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal disease.","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med"},{"key":"R2-23-20210129","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients.","volume":"270","author":"Port","year":"1993","journal-title":"JAMA"},{"key":"R4-23-20210129","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R6-23-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R7-23-20210129","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IgO2 trial.","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R8-23-20210129","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/TP.0b013e3182802f88","article-title":"Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.","volume":"95","author":"Vo","year":"2013","journal-title":"Transplantation"},{"key":"R9-23-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with IVIg for desensitization of renal transplant recipients.","volume":"98","author":"Vo","year":"2014","journal-title":"Transplantation"},{"key":"R10-23-20210129","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.08140910","article-title":"Desensitization protocols and their outcome.","volume":"6","author":"Marfo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R11-23-20210129","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/01.TP.0000438207.42465.40","article-title":"Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant.","volume":"97","author":"Aubert","year":"2014","journal-title":"Transplantation"},{"key":"R12-23-20210129","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1111\/petr.12113","article-title":"Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.","volume":"17","author":"Ryckewaert","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R13-23-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.trim.2012.01.002","article-title":"Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.","volume":"26","author":"Guthoff","year":"2012","journal-title":"Transpl Immunol"},{"key":"R14-23-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications.","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"key":"R15-23-20210129","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ndt\/gfu233","article-title":"Interleukin-6 in renal disease and therapy.","volume":"30","author":"Jones","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R16-23-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody.","volume":"27","author":"Kang","year":"2014","journal-title":"Int Immunol"},{"key":"R17-23-20210129","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R18-23-20210129","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R19-23-20210129","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/TP.0b013e3181da1cc3","article-title":"Combined posttransplant prophylactic IVIganti-CD 20plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.","volume":"89","author":"Loupy","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"R20-23-20210129","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.tmrv.2009.09.010","article-title":"The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline.","volume":"24","author":"Shehata","year":"2010","journal-title":"Transfus Med Rev"},{"key":"R21-23-20210129","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study.","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"R22-23-20210129","first-page":"398","article-title":"Impact of solid phase antibody testing on organ allocation in the United States.","volume":"393-","author":"Reinsmoen","year":"2013","journal-title":"Clin Transpl"},{"key":"R23-23-20210129","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of TregTh17 balance.","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"R24-23-20210129","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trim.2013.03.003","article-title":"Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization.","volume":"28","author":"Wu","year":"2013","journal-title":"Transpl Immunol"},{"key":"R25-23-20210129","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/TP.0000000000000437","article-title":"Anti-Interleukin 6 Receptor Antibodies Attenuate Antibody Recall Responses in a Mouse Model of Allosensitization.","volume":"98","author":"Kim","year":"2014","journal-title":"Transplantation"},{"key":"R26-23-20210129","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/TP.0000000000000525","article-title":"Factors predicting risk for antibody mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization.","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"R27-23-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system.","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"key":"R28-23-20210129","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"R29-23-20210129","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trim.2010.11.006","article-title":"Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab.","volume":"24","author":"Ge","year":"2011","journal-title":"Transpl Immunol"},{"key":"R30-23-20210129","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1097\/00007890-199705270-00023","article-title":"Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction.","volume":"63","author":"Casiraghi","year":"1997","journal-title":"Transplantation"},{"key":"R31-23-20210129","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0272-6386(03)00206-3","article-title":"Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts.","volume":"41","author":"Kwon","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R32-23-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.11622\/smedj.2013174","article-title":"Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients.","volume":"54","author":"Sonkar","year":"2013","journal-title":"Singapore Med J"},{"key":"R33-23-20210129","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/art.38714","article-title":"Tocilizumab treatment leads to a rapid and sustained increase in Treg cell levels in rheumatoid arthritis patients: comment on the article by Thiolat et al.","volume":"66","author":"Sarantopoulos","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000000741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:19:33Z","timestamp":1620976773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201511000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000000741","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}